fitness news
,
Font size Breast Cancer
Breast Cancer: Closer to a Cure?
– Reported, April 18, 2012
(Ivanhoe Newswire)A new study discovered a type of mutation in breast cancer which could help lead to the development of new drugs to treat the devastating disease.
Mayo Clinic researchers found a class of molecular mutations called fusion transcripts which originated in forms of RNA and may also provide a way to identify tumor subtypes and a way to treat them.
Oncologists currently recognize three basic types of breast tumors estrogen-receptor (ER)-positive, HER2-positive, and triple negative.
“But breast cancer is much more complex than indicated by these three subtypes, and one of the challenges of treating the disease is to identify gene markers that predict how a tumor will respond to a specific treatment,” Edith Perez, M.D.,senior investigator, was quoted as saying. “The discovery of subtype-specific fusion transcripts in breast cancer represents a step in this direction,” she said. “Our findings indicate that fusion transcripts are much more common in breast cancer than had been realized. They represent a new class of mutation whose role in breast cancer is not understood at all.”
“Fusion transcripts have the power to produce proteins that are relevant to tumor development, growth, and sensitivity to treatment, so we may have a brand new set of genomic changes that may help us understand, and treat, breast cancer in a new way,” E. Aubrey Thompson, Ph.D., professor of Biology at Mayo Clinic’s Comprehensive Cancer Center, and co-director of the Breast Cancer Translational Genomics Program, was quoted as saying.
“This is a novel discovery that will now require additional investigation,” Thompson said. “We need to understand what these fusion transcripts and proteins are doing.”
Fusion transcripts are created when chromosomes break apart and recombine, an event that commonly occurs in cancer cells. During this process, fusion genes are created when two halves of normal genes become linked. Fusion genes (DNA) create fusion transcripts (RNA), which then produce fusion proteins.
“Mistakes are made,” Dr. Thompson was quoted as saying. “That is one of the salient properties of tumor cells, because they are defective in repairing damage to their genes.”
“These mutated proteins may have an entirely new, cancer-promoting function, or they may interfere with normal cellular functions.”
Blood cancers are a common location that fusion transcripts are found in, such as leukemia and lymphoma. Before this discovery, however, few were found in solid cancers such as breast tumors.
Because fusion genes, transcript, and protein are generally found only in tumors, they make ideal biomarkers to identify tumor cells, Dr. Perez said.
Also, proteins produced by fusion transcripts may be relevant to tumor growth, as has been seen in blood cancers and in lung cancer, Perez was quoted as saying.
“These transcripts may mark regions of localized chromosomal instability that are linked to growth of breast cancer. If we can develop drugs against these transcripts, they will be ideal therapeutic targets,” Dr. Perez said. “We have a lot of exciting work to do in the next few years.
SOURCE: Cancer Research, April 16, 2012
